Company Profile

Azevan Pharmaceuticals Inc (AKA: Serenix Pharmaceuticals Inc)
Profile last edited on: 7/1/2019      CAGE: 473U1      UEI: VHSKTKSAY2S1

Business Identifier: Therapeutics to treat disorders of stress, mood, and behavior
Year Founded
1999
First Award
2000
Latest Award
2020
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

116 Research Drive
Bethlehem, PA 18015
   (610) 419-1057
   N/A
   www.azevan.com
Location: Single
Congr. District: 07
County: Northampton

Public Profile

Formerly known as Serenix Pharmaceuticals, LLC with the name-change to Azevan Pharmaceuticals, Inc. in early 2002, the firm is a clinical stage, small molecule drug development company developing novel therapeutics to treat disorders of stress, mood, and behavior. Developing new molecules that address significant unmet needs in psychiatry through a novel mechanism of action, the Company leverages its expertise in behavioral neurobiology with its proprietary chemistry platform targeting G-protein coupled receptors (GPCRs) to create drug candidates. The Company’s first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of neuropsychiatric symptoms in neurodegenerative diseases and a broad range of stress-related affective disorders, including Post-traumatic Stress Disorder (PTSD), Intermittent Explosive Disorder, and Major Depression. Vasopressin receptor antagonists represent a novel mechanism of action for addressing these indications.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
20-24

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2020 2 NIH $8,825,991
Project Title: Tolerability of SRX246 in Huntington's Disease Patients
2019 1 NIH $501,472
Project Title: A New Drug for the Treatment of Traumatic Brain Injury
2013 2 NIH $2,258,270
Project Title: New Drugs For Stress-Related Affective Illness
2011 1 NIH $141,071
Project Title: Screening New Therapeutics for the Treatment of Post Traumatic Stress Disorder
2009 2 NIH $4,517,005
Project Title: A New Drug for Depression

Key People / Management

  Neal G Simon -- CEO

  Michael J Brownstein

  Eve M Damiano -- VP Operations

  Gary A Koppel